Home » Stocks » HALO

Halozyme Therapeutics, Inc. (HALO)

Stock Price: $47.57 USD -0.12 (-0.25%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 6.88B
Revenue (ttm) 267.59M
Net Income (ttm) 129.09M
Shares Out 136.21M
EPS (ttm) 0.91
PE Ratio 52.27
Forward PE 33.00
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $47.57
Previous Close $47.69
Change ($) -0.12
Change (%) -0.25%
Day's Open 48.15
Day's Range 47.36 - 48.86
Day's Volume 870,638
52-Week Range 22.11 - 56.40

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN DIEGO, April 29, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will present virtually at the BofA Secu...

1 week ago - PRNewsWire

SAN DIEGO, April 20, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2021 on Monday, May 10 at 4:30 p.m. ET / 1:30...

2 weeks ago - PRNewsWire

In some ways, this healthcare stock is outside his wheelhouse. But there could be attractions.

1 month ago - The Motley Fool

It's worth putting a few of your eggs into this basket if you're worried about a big increase in prices.

Other stocks mentioned: BBIO
1 month ago - The Motley Fool

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Sometimes valuation metrics can be deceiving.

Other stocks mentioned: VCEL
2 months ago - The Motley Fool

SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery, today announced the prici...

2 months ago - PRNewsWire

Investors liked what they saw in the company's fourth-quarter earnings release.

2 months ago - The Motley Fool

Halozyme (HALO) reports lower-than-expected fourth-quarter earnings. However, revenues beat estimates.

2 months ago - Zacks Investment Research

Shares of Halozyme Therapeutics (NASDAQ:HALO) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 308.33% over the past year to $0.50, w...

2 months ago - Benzinga

SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery, today announced that it i...

2 months ago - PRNewsWire

Halozyme Therapeutics (NASDAQ:HALO) releases its next round of earnings this Tuesday, February 23. Get the latest predictions in Benzinga's essential guide to the company's Q4 earnings report.

2 months ago - Benzinga

SAN DIEGO, Jan. 15, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Biotech, Inc. (Janssen) has received U.S. Food and Drug Administration (FDA) approval of ...

3 months ago - PRNewsWire

3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic

Other stocks mentioned: BPMC, NVAX
3 months ago - Zacks Investment Research

We highlight a few biotech companies, which outperformed the sector in 2020 and are likely to witness a winning run in the near term.

Other stocks mentioned: BPMC, MRNA
3 months ago - Zacks Investment Research

SAN DIEGO, Dec. 23, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission has approved Roche's Phesgo®, a fixed-dose combination of Perjeta® (pertu...

4 months ago - PRNewsWire

The U.S. healthcare sector emerged as one of the very few sectors that has been able to turn the misfortunes of COVID-19 pandemic to its advantage. The ongoing COVID-19 outbreak and an aging U.S. popula...

Other stocks mentioned: BCRX, QDEL, TDOC, XLRN
4 months ago - Zacks Investment Research

Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.

4 months ago - Zacks Investment Research

Halozyme has settled into its role as a royalty cash machine after transitioning away from a drug discovery company, and the immediate future looks very bright. With 5 products currently on the market a...

5 months ago - Seeking Alpha

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?

5 months ago - Zacks Investment Research

Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.

5 months ago - Zacks Investment Research

Horizon (HZNP) inks deal to get an exclusive access to Halozyme's ENHANZE drug delivery technology for subcutaneous formulation of medicines targeting IGF-1R.

5 months ago - Zacks Investment Research

SAN DIEGO, Nov. 23, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it is updating 2020 financial guidance to reflect the signing of a global collaboration and licen...

5 months ago - PRNewsWire

DUBLIN & SAN DIEGO--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that gives Horizo...

Other stocks mentioned: HZNP
5 months ago - Business Wire

SAN DIEGO, Nov. 18, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will participate in a fireside chat pres...

5 months ago - PRNewsWire

SAN DIEGO, Nov. 13, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has r...

5 months ago - PRNewsWire

SAN DIEGO, Nov. 12, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the Janssen Pharmaceutical Companies submitted regulatory applications to the U.S. Food and Drug ...

5 months ago - PRNewsWire

SAN DIEGO, Nov. 5, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that studies sponsored by Janssen Research & Development, LLC (Janssen) evaluating subcutaneous (SC) da...

6 months ago - PRNewsWire

The shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)  are up 3.6% to trade at $32.77 at last check, after earlier hitting an all-time high of $33.23.

6 months ago - Schaeffers Research

Halozyme Therapeutics boosted its EPS and sales guidance for the year, buoyed by partnerships with big drugmakers such as Roche and Johnson & Johnson, sparking HALO stock to a record high. The post Halo...

6 months ago - Investors Business Daily

Halozyme (HALO) reports better-than-expected third-quarter results. The company raises outlook for the year anticipating higher royalties.

6 months ago - Zacks Investment Research

Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q3 2020 Results - Quick Version Earnings Call Transcript

6 months ago - Seeking Alpha

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 25.00% and 8.86%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

SAN DIEGO, Oct. 6, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Halozyme and argenx are expanding their existing global collaboration and license agreement that w...

7 months ago - PRNewsWire

SAN DIEGO, Sept. 10, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc.

7 months ago - PRNewsWire

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?

7 months ago - Zacks Investment Research

SAN DIEGO, Sept. 2, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc.

8 months ago - PRNewsWire

Halozyme (HALO) reports lower-than-expected Q2 earnings. Shares down.

8 months ago - Zacks Investment Research

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -24.00% and -20.93%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

SAN DIEGO, Aug. 10, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc.

8 months ago - PRNewsWire

Let us take a look at five small biotech companies, NVAX, ICPT, FOLD, RETA, HALO, which are gearing up for their earnings release.

Other stocks mentioned: FOLD, ICPT, NVAX, RETA
9 months ago - Zacks Investment Research

SAN DIEGO, Aug. 4, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc.

9 months ago - PRNewsWire

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

Halozyme Therapeutics: Enhanced Prospects, Expensive Valuations

10 months ago - Seeking Alpha

A bull signal is flashing for Halozyme Therapeutics (HALO), which just came off a record peak

10 months ago - Forbes

SAN DIEGO, June 29, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has approved Roche's Phesgo™ (pertuzumab, trastuzumab...

10 months ago - PRNewsWire

Halozyme Therapeutics (HALO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

10 months ago - Zacks Investment Research

About HALO

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilita... [Read more...]

Industry
Biotechnology
Founded
1998
CEO
Helen Torley
Employees
136
Stock Exchange
NASDAQ
Ticker Symbol
HALO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for HALO stock is "Buy." The 12-month stock price forecast is 49.20, which is an increase of 3.43% from the latest price.

Price Target
$49.20
(3.43% upside)
Analyst Consensus: Buy